These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12492544)

  • 21. Different patterns of cross-reactivity in non-immediate hypersensitivity to heparins: from localized to systemic reactions.
    Poza-Guedes P; González-Pérez R; Canto G
    Contact Dermatitis; 2002 Oct; 47(4):244-5. PubMed ID: 12492535
    [No Abstract]   [Full Text] [Related]  

  • 22. Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period.
    Lammintausta K; Kortekangas-Savolainen O
    Acta Derm Venereol; 2005; 85(6):491-6. PubMed ID: 16396795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Airborne contact dermatitis to tetrazepam in geriatric nurses--a report of 10 cases.
    Landeck L; Skudlik C; John SM
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):680-4. PubMed ID: 21692868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patch testing in cutaneous reactions caused by carbamazepine.
    Alanko K
    Contact Dermatitis; 1993 Nov; 29(5):254-7. PubMed ID: 8112065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Wolkenstein P; Chosidow O; Fléchet ML; Robbiola O; Paul M; Dumé L; Revuz J; Roujeau JC
    Contact Dermatitis; 1996 Oct; 35(4):234-6. PubMed ID: 8957644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patch Testing in Drug Eruptions: Practical Aspects and Literature Review of Eruptions and Culprit Drugs.
    de Groot AC
    Dermatitis; 2022 Jan-Feb 01; 33(1):16-30. PubMed ID: 35029348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patch testing in the detection of cutaneous reactions caused by carbamazepine.
    Liao HT; Hung KL; Wang CF; Chen WC
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1997; 38(5):365-9. PubMed ID: 9401180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed hypersensitivity to tetrazepam.
    Blanco R; Díez-Gómez ML; Gala G; Quirce S
    Allergy; 1997 Nov; 52(11):1146-7. PubMed ID: 9404574
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants.
    Simiand J; Keane PE; Biziere K; Soubrie P
    Arch Int Pharmacodyn Ther; 1989; 297():272-85. PubMed ID: 2567153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed hypersensitivity drug reactions diagnosed by patch testing.
    Calkin JM; Maibach HI
    Contact Dermatitis; 1993 Nov; 29(5):223-33. PubMed ID: 8112060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell involvement in cutaneous drug eruptions.
    Hari Y; Frutig-Schnyder K; Hurni M; Yawalkar N; Zanni MP; Schnyder B; Kappeler A; von Greyerz S; Braathen LR; Pichler WJ
    Clin Exp Allergy; 2001 Sep; 31(9):1398-408. PubMed ID: 11591190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No cross-reactions between tetrazepam and other benzodiazepines: a possible chemical explanation.
    Barbaud A; Girault PY; Schmutz JL; Weber-Muller F; Trechot P
    Contact Dermatitis; 2009 Jul; 61(1):53-6. PubMed ID: 19659970
    [No Abstract]   [Full Text] [Related]  

  • 33. Vesicular Contact Reaction May Progress into Erythema Multiforme.
    Czarnecka-Operacz M; Jenerowicz D; Szulczyńska-Gabor J; Teresiak-Mikołajczak E; Szyfter-Harris J; Bowszyc-Dmochowska M
    Acta Dermatovenerol Croat; 2016 Dec; 24(4):307-309. PubMed ID: 28128086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug eruptions: the value of oral rechallenge test and patch test.
    Puavilai S; Chunharas A; Kamtavee S; Pongwiriyapanich S
    J Med Assoc Thai; 2002 Feb; 85(2):263-9. PubMed ID: 12081129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisphosphonate-induced cutaneous adverse events: the difficulty of assessing imputability through patch testing.
    Barrantes-González M; Espona-Quer M; Salas E; Giménez-Arnau AM
    Dermatology; 2014; 229(3):163-8. PubMed ID: 25323638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The usefulness of skin tests to prove drug hypersensitivity.
    Lammintausta K; Kortekangas-Savolainen O
    Br J Dermatol; 2005 May; 152(5):968-74. PubMed ID: 15888154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents.
    Keane PE; Simiand J; Morre M; Biziere K
    J Pharmacol Exp Ther; 1988 May; 245(2):692-8. PubMed ID: 2896794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnostic value of the sulfite skin test].
    Gay G; Sabbah A; Drouet M
    Allerg Immunol (Paris); 1994 Apr; 26(4):139-40. PubMed ID: 8031458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-sensitivity among oxicams in piroxicam-caused fixed drug eruption: two case reports.
    Ordoqui E; De Barrio M; Rodríguez VM; Herrero T; Gil PJ; Baeza ML
    Allergy; 1995 Sep; 50(9):741-4. PubMed ID: 8546269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Unintended rechallenge : Generalized bullous fixed drug eruption in two elderly women].
    Paulmann M; Mockenhaupt M
    Hautarzt; 2017 Jan; 68(1):59-63. PubMed ID: 27448063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.